Navigation Links
Topokine Announces Dosing of First Subject in a Phase I Clinical Trial of XAF5 Gel for Local Reduction of Subcutaneous Fat
Date:12/5/2012

Newton, MA (PRWEB) December 05, 2012

Topokine Therapeutics has announced that the first subject has been dosed in a repeat-dose, healthy volunteer study of XAF5 Gel, a skin cream for local reduction of excess subcutaneous fat (lipohypertrophy). The study is assessing the safety and tolerability of repeat doses of XAF5 Gel at three concentrations. The study is also quantifying the effects of XAF5 on subcutaneous adipose tissue.

“We are excited to enter clinical development with the first non-invasive, local drug therapy to reduce lipohypertrophy,” said Topokine’s Chief Scientific Officer, Michael Singer, MD, PhD. “We hope to provide a convenient and effective alternative to surgery and injections.”

XAF5 is an adipomodulatory compound that inhibits adipocytes by engaging a cell-surface receptor, resulting in down-regulation of key adipocyte transcription factors. XAF5 reduces adipose tissue in vivo without inflammation or necrosis.

“Topokine’s preclinical data are promising,” said Jeffrey S. Dover, MD, FRCPC, a nationally recognized dermatologist and member of the Company’s Scientific Board of Advisors. “A skin cream that reduces subcutaneous fat would be an attractive proposition for patients and physicians alike.”

The company expects to report top-line results in the first half of 2013.

About Topokine and XAF5 Gel
Topokine Therapeutics is a clinical-stage biotechnology company developing therapies for dermatology and medical aesthetics. The company's lead program, XAF5 Gel, is a skin cream being developed for local reduction of excess subcutaneous fat. XAF5 is an adipomodulatory compound that inhibits adipocytes by engaging a cell-surface receptor, resulting in down-regulation of key adipocyte transcription factors. XAF5 reduces adipose tissue in vivo without inflammation or necrosis.

Forward-Looking Statements
This press release contains forward-looking statements regarding the development of XAF5. These statements are based on Topokine’s current beliefs and expectations, but actual results may differ.

Read the full story at http://www.prweb.com/releases/2012/12/prweb10203404.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Biocartis Announces Commercial Launch of a New Biomarker Analysis Platform
2. Chemical Publishing Company Announces its Niche Catalog in the Water Technology and Water Treatment Space
3. Japan Bioinformatics Announces Study on Leading Mapping Tools for DNA Mutation Discovery
4. The Scientist Proudly Announces the Top 10 Innovations of 2012
5. Bayer CropScience Announces LibertyLink LinkUp Offer Increased for 2013 Season
6. IntelliCell BioSciences Announces Research Agreement with the New Jersey Center for Biomaterials at Rutgers-The State University of New Jersey
7. Genomic Health Announces Presentation of Six Studies at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium
8. Smith & Nephew Announces Agreement To Acquire Assets Of Healthpoint Biotherapeutics
9. Ampio Pharmaceuticals, Inc. (AMPE) announces appointment of Josh Disbrow as Chief Operating Officer effective December 15, 2012
10. Amarantus BioSciences Announces Positive Data for MANF in Delivery Diffusion Animal Model of Parkinsons Disease
11. BioRestorative Therapies Announces Launch of New Website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/7/2020)... ... January 07, 2020 , ... Absolute ... announced the launch of its VivopureX™ recombinant mouse antibodies for in vivo research ... from rats or hamsters, which Absolute Antibody has engineered into mouse-anti-mouse recombinant versions ...
(Date:1/7/2020)... ... January 06, 2020 , ... ... announced its expansion into whole-home smart lighting with two new products: the Brilliant ... the ability for homeowners and homebuilders to affordably add high-end smart lighting to ...
(Date:12/31/2019)... ... December 31, 2019 , ... At this year's SLAS conference, Visikol ... broadly focused on 3D cell culture , advanced imaging and ... assays for assessing steatosis , inflammation and fibrosis as well as ...
(Date:12/27/2019)... ... December 27, 2019 , ... Vici ... 505(b)(2) product pipeline that offers patients and healthcare providers options in ... were identified in collaboration with doctors and managed care professionals and developed at ...
Breaking Biology Technology:
(Date:1/24/2020)... ... 2020 , ... Shoreline Biome , a microbiome research company that develops ... company will debut a novel new DNA isolation kit at the Miami Winter ... Rapid Prep kit, is a fast and easy-to-use kit designed for the efficient and ...
(Date:1/24/2020)... ... January 24, 2020 , ... The Rockies ... capital resources to support early-stage bioscience companies in the state. , ... to find the funding they need to innovate and grow. This program ...
(Date:1/24/2020)... ... January 24, 2020 , ... Worldwide Business with ... President Dr. Stanley Stanbridge and Vice President of Sales and Marketing Jeff Maier to ... Network as sponsored content on Sunday, Jan. 26, 2020 at 5:30 p.m. EST and ...
Breaking Biology News(10 mins):